ARCUTIS BIOTHERAPEUTICS INC. - COMMON STOCK

Nationwide Survey of People with Seborrehic Dermatitis Reveals Dissatisfaction with Current Treatment Options and Burden of Daily Care

25 5 2022 07:00:01 提供 Nasdaq GlobeNewswire

Arcutis Announces First Quarter 2022 Financial Results and Provides Business Update

05 5 2022 15:01:01 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 5 2022 07:00:04 提供 Nasdaq GlobeNewswire

Arcutis Completes Enrollment in ARRECTOR Pivotal Phase 3 Trial of Topical Roflumilast Foam in Scalp and Body Psoriasis

06 4 2022 07:00:01 提供 Nasdaq GlobeNewswire

Arcutis Highlights Growth Opportunities at Investor Day in Advance of 2022 Catalysts

28 3 2022 07:00:01 提供 Nasdaq GlobeNewswire

Arcutis Presents New Data on Once-Daily Roflumilast Cream for Plaque Psoriasis from DERMIS Phase 3 Trials at American Academy of Dermatology Annual Meeting

25 3 2022 06:30:00 提供 Nasdaq GlobeNewswire

Arcutis’ Roflumilast Foam Demonstrates Clinically Meaningful Results and Patient Quality of Life Improvements in Phase 2 Seborrheic Dermatitis Study

25 3 2022 06:30:00 提供 Nasdaq GlobeNewswire

National Survey Reveals Insights into Emotional Impact of Psoriasis and Illuminates Need for New Topical Treatments

22 3 2022 07:00:02 提供 Nasdaq GlobeNewswire

Arcutis to Host Investor Day on March 28

21 3 2022 07:00:01 提供 Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 3 2022 15:05:00 提供 Nasdaq GlobeNewswire